Cargando…

Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling

Despite androgen deprivation therapy (ADT) suppression of prostate cancer (PCa) growth, its overall effects on PCa metastasis remain unclear. Using human (C4-2B/THP1) and mouse (TRAMP-C1/RAW264.7) PCa cells–macrophages co-culture systems, we found currently used anti-androgens, MDV3100 (enzalutamide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, T-H, Izumi, K, Lee, S O, Lin, W-J, Yeh, S, Chang, C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3763432/ https://www.ncbi.nlm.nih.gov/pubmed/23928703 http://dx.doi.org/10.1038/cddis.2013.270

Ejemplares similares

Influence of Androgen Receptor Antagonist MDV3100 Therapy on Rats With Benign Prostatic Hyperplasia
por: Yang, Minggen, et al.
Publicado: (2021)

Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients
por: Heck, Matthias M., et al.
Publicado: (2013)

Enzalutamide: the emperor of all anti-androgens
por: Antonarakis, Emmanuel S.
Publicado: (2013)

Clinical Efficacy of Enzalutamide vs Bicalutamide Combined With Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Clinical Trial
por: Vaishampayan, Ulka N., et al.
Publicado: (2021)

Ailanthone targets p23 to overcome MDV3100 resistance in castration-resistant prostate cancer
por: He, Yundong, et al.
Publicado: (2016)

Abiraterone and MDV3100 inhibits the proliferation and promotes the apoptosis of prostate cancer cells through mitophagy
por: Han, Jingli, et al.
Publicado: (2019)

Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog–Thalidomide PROTACs
por: Kim, Ga Yeong, et al.
Publicado: (2021)

Efficacy of Immediate Switching from Bicalutamide to Flutamide as Second-Line Combined Androgen Blockade
por: Yokomizo, Yumiko, et al.
Publicado: (2016)

Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor
por: Coleman, Daniel J., et al.
Publicado: (2016)

Charge density view on bicalutamide molecular interactions in the monoclinic polymorph and androgen receptor binding pocket
por: Korlyukov, Alexander A., et al.
Publicado: (2020)

Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide
por: Cochrane, Dawn R, et al.
Publicado: (2014)

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)
por: Iguchi, Taro, et al.
Publicado: (2019)

Response to flutamide, as second-line therapy after bicalutamide, predicts efficacy of abiraterone, not that of enzalutamide
por: Nakai, Yasushi, et al.
Publicado: (2018)

Androgen receptor, ccl2, and epithelial-mesenchymal transition: A dangerous affair in the tumor microenvironment
por: Lin, Wen-Jye, et al.
Publicado: (2014)

Synergic prodegradative activity of Bicalutamide and trehalose on the mutant androgen receptor responsible for spinal and bulbar muscular atrophy
por: Giorgetti, Elisa, et al.
Publicado: (2015)

Efficacy of Bicalutamide 150-mg Monotherapy Compared With Combined Androgen Blockade in Patients With Locally Advanced Prostate Cancer
por: Kang, Yu Jin, et al.
Publicado: (2014)

Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer
por: Lu, Qianyi, et al.
Publicado: (2019)

Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone
por: Kanao, Kent, et al.
Publicado: (2022)

Enzalutamide induced non-ischemic cardiomyopathy. A case report and review of literature on anti-androgen therapy-related cardiovascular events
por: Kumar, Aswini, et al.
Publicado: (2023)

Targeting inflammatory cytokines-androgen receptor (AR) signaling with ASC-J9(®) to better battle prostate cancer progression
por: Izumi, Kouji, et al.
Publicado: (2013)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
por: Zhang, Haozhe, et al.
Publicado: (2022)

Bicalutamide, an androgen receptor antagonist, effectively alleviate allergic rhinitis via suppression of PI3K–PKB activity
por: Zhang, Yu, et al.
Publicado: (2022)

Preclinical studies using cisplatin/carboplatin to restore the Enzalutamide sensitivity via degrading the androgen receptor splicing variant 7 (ARv7) to further suppress Enzalutamide resistant prostate cancer
por: Chou, Fu-Ju, et al.
Publicado: (2020)

An Update on Plant Derived Anti-Androgens
por: Grant, Paul, et al.
Publicado: (2012)

Snail promotes resistance to enzalutamide through regulation of androgen receptor activity in prostate cancer
por: Ware, Kathryn E., et al.
Publicado: (2016)

Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system
por: Culig, Z, et al.
Publicado: (1999)

SAT-748 Advantages and Limitations of an Integrative Measurement for All Serum Androgens and Anti-Androgens
por: Schaufele, Fred J, et al.
Publicado: (2020)

Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer
por: Abd. Wahab, Nurul Azwa, et al.
Publicado: (2020)

Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation
por: Izumi, Kouji, et al.
Publicado: (2013)

Androgen receptor-mediated upregulation of quaking affects androgen receptor-related prostate cancer development and anti-androgen receptor therapy
por: Zhang, Keke, et al.
Publicado: (2018)

Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial
por: Penson, David F., et al.
Publicado: (2021)

STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide
por: Rocha, Sandra M., et al.
Publicado: (2023)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance
por: Alumkal, Joshi J., et al.
Publicado: (2020)

Histone acetyltransferase 1 upregulates androgen receptor expression to modulate CRPC cell resistance to enzalutamide
por: Hong, Zhe, et al.
Publicado: (2021)

Anti-androgenic effects of flavonols in prostate cancer
por: Boam, Tristan
Publicado: (2015)

Food components and contaminants as (anti)androgenic molecules
por: Marcoccia, Daniele, et al.
Publicado: (2017)

Androgens and Androgen Receptor Actions on Bone Health and Disease: From Androgen Deficiency to Androgen Therapy
por: Chen, Jia-Feng, et al.
Publicado: (2019)

4-Nitro-3-phenylphenol has both androgenic and anti-androgenic-like effects in rats
por: TRISOMBOON, Jiratthiya, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_12oges4jjb6iv84s86nj4vhpg4